Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment

We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing stocks on Tuesday.

Liquidia soared by 10.67 percent on Tuesday to close at $27.91 apiece, just 92 cents shy of its highest 52-week price, as investor sentiment was bolstered by strong demand for its pulmonary hypertension treatment.

In an updated report, Liquidia Corp. (NASDAQ:LQDA) said that total revenues in the third quarter of the year soared by 1,134 percent to $54 million from $4.4 million in the same period last year, on the back of a strong sales performance from its Yutrepia treatment.

Pixabay/Public Domain

Of the total revenues, product sales stood at $51.7 million, while service revenues ended at $2.67 million.

The strong performance helped the company narrow its net loss for the third quarter by 89 percent to $3.5 million from $31.03 million in the same comparable period.

“Our third quarter results demonstrate the continued momentum of Yutrepia’s launch and the clear enthusiasm from both prescribers and patients. As of October 30, 2025, we have received more than 2,000 unique prescriptions and shipped to more than 1,500 patients, supported by over 600 prescribers nationwide,” said Liquidia Corp. (NASDAQ:LQDA) CEO Roger Jeffs.

“With the strong foundation established in our first full quarter post-launch, we are well positioned to pursue sustained growth and continued profitability, while thoughtfully investing in programs to expand Yutrepia’s therapeutic profile and advance L606 into pivotal trials,” he noted.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.